Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy Subjects
- 21 November 2008
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 49 (5) , 513-519
Abstract
Objective: To characterize the effect of efavirenz on bupropion hydroxylation as a marker of cytochrome P450 (CYP) 2B6 activity in healthy subjects. Methods: Thirteen subjects received a single oral dose of bupropion SR 150 mg before and after 2 weeks of efavirenz administration for comparison of bupropion and hydroxybupropion pharmacokinetics. Efavirenz plasma concentrations were also assessed. Subjects were genotyped for CYP2B6 (G516T, C1459T, and A785G), CYP3A4 (A-392G), CYP3A5 (A6986G), and multidrug resistance protein 1 (C3435T). Results: The area under the concentration vs. time curve ratio of hydroxybupropion:bupropion increased 2.3-fold after efavirenz administration (P = 0.0001). Bupropion area under the concentration vs. time curve and Cmax decreased by 55% and 34%, respectively (P < 0.002). None of the CYP2B6 or CYP3A genotypes evaluated were associated with a difference in bupropion or efavirenz clearance. The 2 individuals homozygous for multidrug resistance protein 1 3435-T/T had 2.5- and 1.8-fold greater bupropion and efavirenz clearance, respectively, relative to C/C and C/T individuals (P < 0.05). Conclusions: Our results confirm that efavirenz induces CYP2B6 enzyme activity in vivo, as demonstrated by an increase in bupropion hydroxylation after 2 weeks of efavirenz administration.Keywords
This publication has 31 references indexed in Scilit:
- Effect of renal impairment on the pharmacokinetics of bupropion and its metabolitesBritish Journal of Clinical Pharmacology, 2007
- Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 InducersThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissuesPharmacogenetics and Genomics, 2006
- Bupropion for major depressive disorder: Pharmacokinetic and formulation considerationsClinical Therapeutics, 2005
- Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimensBiochemical and Biophysical Research Communications, 2004
- REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERSDrug Metabolism and Disposition, 2004
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Population pharmacokinetic meta-analysis with efavirenzInt. Journal of Clinical Pharmacology and Therapeutics, 2002
- Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking CessationDrugs, 2002
- Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessationNicotine & Tobacco Research, 2001